Samsung Biologics (KRX:207940), a South Korea-based contract development and manufacturing organisation (CDMO), announced on Tuesday that it has achieved a 'Negligible Risk' rating in the latest Morningstar Sustainalytics ESG Risk Ratings assessment, marking further progress in its environmental, social, and governance (ESG) performance.

Samsung Biologics received an ESG Risk Rating score of 9.0, advancing from its previous 'Low Risk' rating to 'Negligible Risk,' the lowest of five risk categories. This result places the company among the top 0.5% of companies assessed in the pharmaceuticals industry.

Morningstar Sustainalytics, a Netherlands-based, independent ESG research and ratings provider, assesses approximately 16,000 companies worldwide based on their exposure to material ESG risks and how effectively those risks are managed. Under its methodology, scores below 10 indicate a negligible level of unmanaged ESG risk, with lower scores reflecting lower overall risk.

Samsung Biologics said it has implemented initiatives to enhance environmental auditing, occupational health and safety, quality management, and business ethics, while reinforcing internal processes and oversight to identify and address potential risks.

The achievement follows Samsung Biologics' recent 'A' rating in the 2026 MSCI ESG Ratings assessment. Earlier this year, the company also received the EcoVadis Platinum Sustainability Rating, placing it among the top 1% of companies assessed globally.